Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Is disorganized schizophrenia a predictor of treatment resistance? Evidence from an observational study.

Ortiz BB, Ara├║jo Filho GM, Araripe Neto AG, Medeiros D, Bressan RA.

Rev Bras Psiquiatr. 2013 Oct-Dec;35(4):432-4. doi: 10.1590/1516-4446-2013-1190. Epub 2013 Dec 23.

2.

Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?

Corves C, Engel RR, Davis J, Leucht S.

Acta Psychiatr Scand. 2014 Jul;130(1):40-5. doi: 10.1111/acps.12231. Epub 2013 Dec 2.

PMID:
24299424
3.

Benefits of combining aripiprazole to clozapine: three case reports.

Rocha FL, Hara C.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1167-9. Epub 2006 May 2.

PMID:
16647796
4.

Can clozapine response be predicted? A naturalistic pilot study.

Fenton WS, Lee B.

J Nerv Ment Dis. 1993 Jan;181(1):62-4. No abstract available.

PMID:
8419518
5.

Clozapine shows promise in schizophrenia treatment.

Smith R, Sukowatey M, Solko K, Christensen J, Saak J, Burnham A.

Iowa Med. 1993 Jul;83(7):261-3.

PMID:
8365868
6.

An open comparison of clozapine and risperidone in treatment-resistant schizophrenia.

Flynn SW, MacEwan GW, Altman S, Kopala LC, Fredrikson DH, Smith GN, Honer WG.

Pharmacopsychiatry. 1998 Jan;31(1):25-9.

PMID:
9524981
7.

Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.

Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, Mamo DC.

Br J Psychiatry. 2011 Oct;199(4):275-80. doi: 10.1192/bjp.bp.110.083907. Review.

8.

Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports.

Chong SA, Tan CH, Lee HS.

J Clin Psychopharmacol. 1997 Feb;17(1):68-9. No abstract available.

PMID:
9004072
9.

Amoxapine as an antipsychotic: comparative study versus haloperidol.

Chaudhry IB, Husain N, Khan S, Badshah S, Deakin B, Kapur S.

J Clin Psychopharmacol. 2007 Dec;27(6):575-81.

PMID:
18004123
10.

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.

Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB.

Schizophr Bull. 2006 Oct;32(4):715-23. Epub 2006 Mar 15.

11.

An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia.

Turetz M, Mozes T, Toren P, Chernauzan N, Yoran-Hegesh R, Mester R, Wittenberg N, Tyano S, Weizman A.

Br J Psychiatry. 1997 Jun;170:507-10.

PMID:
9330014
12.

Effects of sertindole on cognition in clozapine-treated schizophrenia patients.

Nielsen RE, Levander S, Thode D, Nielsen J.

Acta Psychiatr Scand. 2012 Jul;126(1):31-9. doi: 10.1111/j.1600-0447.2012.01840.x. Epub 2012 Feb 22.

PMID:
22356584
13.

Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.

Kelly DL, Feldman S, Boggs DL, Gale E, Conley RR.

Compr Psychiatry. 2010 May-Jun;51(3):298-302. doi: 10.1016/j.comppsych.2009.07.003. Epub 2009 Aug 27.

PMID:
20399340
14.

Augmentation of clozapine's antiagressive properties with lamotrigine in a patient with chronic disorganized schizophrenia.

Pavlovic ZM.

J Clin Psychopharmacol. 2008 Feb;28(1):119-20. doi: 10.1097/jcp.0b013e3181603f48. No abstract available.

PMID:
18204363
15.

Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.

Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M, Chiavacci MC, Bottai M, Ramacciotti CE, Cassano GB.

J Clin Psychiatry. 2003 Apr;64(4):451-8.

PMID:
12716249
16.

Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.

Zink M, Kuwilsky A, Krumm B, Dressing H.

J Psychopharmacol. 2009 May;23(3):305-14. doi: 10.1177/0269881108089593. Epub 2008 Jun 18.

PMID:
18562423
17.

Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.

Mortimer AM, Singh P, Shepherd CJ, Puthiryackal J.

Clin Schizophr Relat Psychoses. 2010 Apr;4(1):49-55. doi: 10.3371/CSRP.4.1.4.

PMID:
20643629
18.

Clozapine augmentation with aripiprazole for negative symptoms.

Clarke LA, Lindenmayer JP, Kaushik S.

J Clin Psychiatry. 2006 Apr;67(4):675-6. No abstract available.

PMID:
16669737
19.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

20.

Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.

Semiz UB, Cetin M, Basoglu C, Ebrinc S, Uzun O, Herken H, Balibey H, Algul A, Ates A.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1330-6. Epub 2007 Jun 12.

PMID:
17618026

Supplemental Content

Support Center